Drug Pipeline

Ranibizumab Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
10
Active Studies
4
Recruiting
7
Phase 3
6
Top Sponsors
3
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-10 NCT06176352
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal…
Trial completed
2026-05-27 NCT06847542
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
date change Primary completion pushed: 2028-09-12 -> 2028-11-15
2026-05-27 NCT06847542
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
date change Completion pushed: 2028-10-12 -> 2028-11-15
Active Studies by Phase
Phase 4
1
Phase 3
5
Phase 2/3
2
Phase 2
1
Phase 1/2
1
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT04853251 A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related… Neovascular Age-related Macular Degeneration Recruiting
Phase 3
NCT07515079 Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema Diabetic Macular Edema (DME) Recruiting
NCT06847542 A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD Neovascular Age-related Macular Degeneration Recruiting
NCT05562947 A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System… Neovascular Age-related Macular Degeneration Recruiting
NCT04657289 A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the… Neovascular Age-related Macular Degeneration (nAMD) Active, Not Recruiting
NCT04444492 Combination of Ranibizumab and Targeted Laser Photocoagulation Central Retinal Vein Occlusion With Macular Edema Active, Not Recruiting
Phase 2/3
NCT06957080 A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME Diabetic Macular Edema (DME) Active, Not Recruiting
NCT04704921 Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via… AMD Active, Not Recruiting
Phase 2
NCT04514653 RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With… Neovascular Age-Related Macular Degeneration (nAMD) Active, Not Recruiting
Phase 1/2
NCT04567303 Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration Macular Degeneration Active, Not Recruiting
Sponsors Running Ranibizumab Trials
Get alerts when Ranibizumab trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free